Idris Boudhabhay Marion Rabant Lubka T Roumenina Louis-Marie Coupry Victoria Poillerat Armance Marchal Véronique Frémeaux-Bacchi Khalil El Karoui Mehran Monchi Franck Pourcine
10.3389/fimmu.2021.680567
Front Immunol
2021 Jun 23;12:680567.
covid-19 case report complement system eculizumab multisystem inflammatory syndrome thrombotic microangiopathy
CC BY
https://pubmed.ncbi.nlm.nih.gov/34248962/
Antibodies, Monoclonal, Humanized / therapeutic use COVID-19 / diagnosis Complement Inactivating Agents / therapeutic use Kidney / metabolism SARS-CoV-2 / physiology Systemic Inflammatory Response Syndrome / diagnosis Thrombotic Microangiopathies / diagnosis
Antibodies, Monoclonal, Humanized / therapeutic use COVID-19 / diagnosis Complement Inactivating Agents / therapeutic use Kidney / metabolism SARS-CoV-2 / physiology Systemic Inflammatory Response Syndrome / diagnosis Thrombotic Microangiopathies / diagnosis Case Reports COVID-19 Drug Treatment Humans Kidney / pathology Male Middle Aged Pandemics Recovery of Function Systemic Inflammatory Response Syndrome / drug therapy Thrombotic Microangiopathies / drug therapy Antibodies, Monoclonal, Humanized Complement Inactivating Agents adult multisystem inflammatory disease, COVID-19 related eculizumab
PMC8260674
34248962
Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy
2021